Medifast, Inc., through its subsidiaries, manufactures and distributes weight loss, weight management, healthy living products, and other consumable health and nutritional products in the United States and the Asia-Pacific. It offers bars, bites, pretzels, puffs, cereal crunch, drinks, hearty choices, oatmeal, pancakes, puddings, soft serves, shakes, smoothies, soft bakes, and soups under the Medifast, OPTAVIA, Thrive by Medifast, Optimal Health by Take Shape for Life, and Flavors of Home brands. The company markets its products through point of sale transactions over ecommerce platform and its franchisee system. Medifast, Inc. was founded in 1980 and is headquartered in Baltimore, Maryland.
IPO Year:
Exchange: NYSE
Website: medifastinc.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 11/5/2024 | $16.50 → $17.00 | Underperform → Neutral | DA Davidson |
| 6/5/2024 | $25.00 → $17.50 | Neutral → Underperform | DA Davidson |
| 10/13/2023 | $82.00 | Equal-Weight | Stephens |
| 11/4/2022 | $278.00 → $106.00 | Buy → Neutral | DA Davidson |
| 8/4/2022 | $345.00 → $150.00 | Buy → Hold | Jefferies |
| 2/24/2022 | $349.00 → $341.00 | Buy | DA Davidson |
| 11/8/2021 | $395.00 → $349.00 | Buy | DA Davidson |
Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.
4 - MEDIFAST INC (0000910329) (Issuer)
4 - MEDIFAST INC (0000910329) (Issuer)
4 - MEDIFAST INC (0000910329) (Issuer)
4 - MEDIFAST INC (0000910329) (Issuer)
4 - MEDIFAST INC (0000910329) (Issuer)
4 - MEDIFAST INC (0000910329) (Issuer)
8-K - MEDIFAST INC (0000910329) (Filer)
8-K - MEDIFAST INC (0000910329) (Filer)
SCHEDULE 13G/A - MEDIFAST INC (0000910329) (Subject)
10-Q - MEDIFAST INC (0000910329) (Filer)
8-K - MEDIFAST INC (0000910329) (Filer)
DEF 14A - MEDIFAST INC (0000910329) (Filer)
DEFA14A - MEDIFAST INC (0000910329) (Filer)
SCHEDULE 13G/A - MEDIFAST INC (0000910329) (Subject)
8-K - MEDIFAST INC (0000910329) (Filer)
10-K - MEDIFAST INC (0000910329) (Filer)
Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.
4 - MEDIFAST INC (0000910329) (Issuer)
4 - MEDIFAST INC (0000910329) (Issuer)
4 - MEDIFAST INC (0000910329) (Issuer)
4 - MEDIFAST INC (0000910329) (Issuer)
4 - MEDIFAST INC (0000910329) (Issuer)
4 - MEDIFAST INC (0000910329) (Issuer)
3 - MEDIFAST INC (0000910329) (Issuer)
3 - MEDIFAST INC (0000910329) (Issuer)
4 - MEDIFAST INC (0000910329) (Issuer)
3 - MEDIFAST INC (0000910329) (Issuer)
Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.
DA Davidson upgraded Medifast from Underperform to Neutral and set a new price target of $17.00 from $16.50 previously
DA Davidson downgraded Medifast from Neutral to Underperform and set a new price target of $17.50 from $25.00 previously
Stephens initiated coverage of Medifast with a rating of Equal-Weight and set a new price target of $82.00
DA Davidson downgraded Medifast from Buy to Neutral and set a new price target of $106.00 from $278.00 previously
Jefferies downgraded Medifast from Buy to Hold and set a new price target of $150.00 from $345.00 previously
DA Davidson reiterated coverage of Medifast with a rating of Buy and set a new price target of $341.00 from $349.00 previously
DA Davidson reiterated coverage of Medifast with a rating of Buy and set a new price target of $349.00 from $395.00 previously
DA Davidson reiterated coverage of Medifast with a rating of Buy and set a new price target of $395.00 from $302.00 previously
DA Davidson reiterated coverage of Medifast with a rating of Buy and set a new price target of $302.00 from $239.00 previously
DA Davidson reiterated coverage of Medifast with a rating of Buy and set a new price target of $302.00 from $239.00 previously
Fastest customizable press release news feed in the world
Johnson will succeed Dan Chard as CEO; Chard to remain Chairman of the Board Medifast, Inc. (NYSE:MED) today announced that its Board of Directors has formally appointed Nicholas Johnson as Chief Executive Officer, effective June 1, 2026. Johnson will succeed Dan Chard as CEO, who will continue to serve as Chairman of the Board. The appointment follows the leadership transition plan that the company disclosed in January and reflects the Board's confidence in Johnson's leadership and the company's strategic direction. Chard will remain actively engaged as Chairman of the Board, supporting Johnson and the leadership team while continuing to provide strategic oversight. "Nick has been a
A randomized controlled trial published in Obesity Science & Practice found that clients on the OPTAVIA Optimal Weight 5 & 1 Plan® who worked with a coach lost significantly more weight and fat than those who attempted the program without coaching support (Arterburn LM, et al., 2019)Higher retention in a weight management program is directly correlated with more significant weight loss outcomes, per a 2024 systematic review and meta-analysisOPTAVIA coaches complete a program-specific education curriculum and must pass a certification exam before supporting participantsIndependent research commissioned by OPTAVIA found that 96% of Americans recognize lifestyle changes are essential for weight
70% of users discontinued use of lifestyle behavior and health apps within the first 100 days (Kidman PG, et al., 2024)Early weight loss at week four is a strong predictor of clinically relevant outcomes, with research identifying additional counseling and support as key for those showing lower early progress (Coleman CD, et al., 2023)Accountability and self-monitoring are among the most commonly reported factors in sustaining weight loss results, according to a research survey of OPTAVIA coaches and clients (Coleman CD, et al., 2022)In a peer-reviewed clinical trial, participants working with a coach lost up to 10 times more weight and 17 times more fat, and achieved a 14% reduction in visc
Body composition, specifically visceral fat levels and lean mass, plays a meaningful role in long-term metabolic health (Serra MC, et al., 2019)Structured plans, habit building, and dedicated coach support work together to produce body composition outcomes that reflect the quality of weight loss, not just its quantity (Arterburn LM, et al., 2019)High-quality protein, nutrient density, and scientifically developed nutrition, combined with structured plans and habit building, support visceral fat reduction and lean mass preservation during weight loss Human accountability and coach support can lead to stronger outcomes in sustained behavior change and weight management success (Arterburn LM, e
The global weight loss industry was valued at $16.3 billion in 2025, yet peer-reviewed clinical validation of program outcomes remains uneven across the categoryRandomized controlled trials control for the lifestyle variables and selection bias that self-reported program data cannot account for, making them the standard for evaluating whether a weight loss program itself is driving outcomesBody composition is the breakdown of fat, lean mass, and bone. It shows what weight loss is actually made up of, a distinction that scale weight alone cannot captureA coach can address the specific barriers that may cause program adherence to stall, providing an additional support compared to digital track
Medifast (NYSE:MED), the metabolic health and wellness company known for its science-backed, coach-guided lifestyle system, today reported results for the first quarter ended March 31, 2026. First Quarter 2026 Revenue of $76.0 million, with revenue per active earning coach of $5,432 Independent active earning coaches of 14,000 Net loss of $2.1 million, or $0.19 per diluted share ("EPS") Cash, Cash Equivalents, and Investment Securities of $168.9 million with no debt "We are encouraged by the continued progress we are seeing as we execute our metabolic health strategy, including a second consecutive quarter of year-over-year coach productivity growth, strong coach leadership
Medifast (NYSE:MED), the metabolic health and wellness company known for its science-backed, coach-guided lifestyle system, will announce financial results for the quarter ended March 31, 2026 on Monday, May 4, 2026, after market close. The Company will host a conference call to discuss the results with additional comments and details. Company participants will be Dan Chard, Chairman and Chief Executive Officer, Nick Johnson, President, and Jim Maloney, Chief Financial Officer. The conference call is scheduled to begin at 4:30 p.m. ET on May 4, 2026. The call will be broadcast live over the Internet, hosted on the Investor Relations section of Medifast's website at www.MedifastInc.com or
Company Agrees to Nominate Parsa Kiai and Jeff Rose as Director Candidates at 2026 Annual Meeting of Stockholders Medifast, Inc. (NYSE:MED), the metabolic health and wellness company known for its science-backed, coach-guided lifestyle system, today announced the company's Board of Directors has agreed to nominate Parsa Kiai and Jeff Rose from Steamboat Capital Partners LLC as independent director candidates to stand for election at the company's 2026 Annual Meeting of Stockholders, which is provisionally scheduled for May 19, 2026. These nominations are pursuant to a Cooperation Agreement entered into between the company and Steamboat Capital, which beneficially owns above 5% of the comp
As part of its continued focus on improving metabolic health, Medifast® (NYSE:MED) today announced that OPTAVIA's comprehensive metabolic health system is available for reimbursement on select insurance plans using Health Savings Accounts (HSA) and Flexible Spending Accounts (FSA). OPTAVIA clients may be able to save up to 40% on program costs by working with their medical provider and insurance administrator to use pre-tax medical funds, offering accessibility for those prioritizing their metabolic health. This milestone reinforces Medifast's position as a science-driven health and wellness leader, with a metabolic reset plan that reverses metabolic dysfunction — a widespread but often o
Medifast (NYSE:MED), the health and wellness company known for its science-backed, coach-guided lifestyle system, today reported results for the fourth quarter and full year ended December 31, 2025. Fourth Quarter 2025 Revenue of $75.1 million, with revenue per active earning coach of $4,664 Independent active earning coaches of 16,100 Net loss of $18.1 million, or $1.65 per diluted share ("EPS"), which includes the tax provision charge to establish a non-cash valuation allowance on the Company's deferred tax balance of $12.1 million (or $1.10 per diluted share) Cash, cash equivalents, and investment Securities of $167.3 million and no debt Full Year 2025 Revenue of $385
This live feed shows all institutional transactions in real time.
SC 13G/A - MEDIFAST INC (0000910329) (Subject)
SC 13G - MEDIFAST INC (0000910329) (Subject)
SC 13G/A - MEDIFAST INC (0000910329) (Subject)
SC 13G/A - MEDIFAST INC (0000910329) (Subject)
SC 13G/A - MEDIFAST INC (0000910329) (Subject)
SC 13G/A - MEDIFAST INC (0000910329) (Subject)
Live Leadership Updates
Johnson will succeed Dan Chard as CEO; Chard to remain Chairman of the Board Medifast, Inc. (NYSE:MED) today announced that its Board of Directors has formally appointed Nicholas Johnson as Chief Executive Officer, effective June 1, 2026. Johnson will succeed Dan Chard as CEO, who will continue to serve as Chairman of the Board. The appointment follows the leadership transition plan that the company disclosed in January and reflects the Board's confidence in Johnson's leadership and the company's strategic direction. Chard will remain actively engaged as Chairman of the Board, supporting Johnson and the leadership team while continuing to provide strategic oversight. "Nick has been a
Nicholas Johnson Appointed President, and Expected to Succeed Dan Chard as CEO in June 2026; Chard to Remain Chairman Medifast, Inc. (NYSE:MED) today announced a planned leadership transition designed to provide continuity and stability as the company continues its evolution toward metabolic health. Medifast Chairman & Chief Executive Officer Dan Chard has informed the Board of Directors that he plans to step down as Chief Executive Officer in June 2026. Chard will continue to serve as Chairman of the Board following the transition. The Board has appointed Medifast's Chief Field Operations Officer Nicholas Johnson as President of Medifast, effective immediately. Johnson will work clo
NEW YORK, June 7, 2024 /PRNewswire/ -- S&P Dow Jones Indices ("S&P DJI") will make the following changes to the S&P 500, S&P MidCap 400, and S&P SmallCap 600 indices effective prior to the open of trading on Monday, June 24, to coincide with the quarterly rebalance. The changes ensure each index is more representative of its market capitalization range. All companies being added to the S&P 500 are more representative of the large-cap market space, all companies being added to the S&P MidCap 400 are more representative of the mid-cap market space, and all companies being added to the S&P SmallCap 600 are more representative of the small-cap market space. The companies being removed from the S
BALTIMORE, March 2, 2023 /PRNewswire/ -- Medifast (NYSE:MED), the global company behind one of the fastest-growing health and wellness communities, OPTAVIA®, today announced it has named Steven Zenker as Vice President of Investor Relations. Mr. Zenker has over 30 years of investor relations, financial planning and analysis, communications, and investment management experience. He reports to Chief Financial Officer Jim Maloney and will lead the strategy and continued implementation of the company's investor relations program. "We are pleased to welcome Steven to the Medifast t
Live finance-specific insights
Medifast (NYSE:MED), the metabolic health and wellness company known for its science-backed, coach-guided lifestyle system, today reported results for the first quarter ended March 31, 2026. First Quarter 2026 Revenue of $76.0 million, with revenue per active earning coach of $5,432 Independent active earning coaches of 14,000 Net loss of $2.1 million, or $0.19 per diluted share ("EPS") Cash, Cash Equivalents, and Investment Securities of $168.9 million with no debt "We are encouraged by the continued progress we are seeing as we execute our metabolic health strategy, including a second consecutive quarter of year-over-year coach productivity growth, strong coach leadership
Medifast (NYSE:MED), the metabolic health and wellness company known for its science-backed, coach-guided lifestyle system, will announce financial results for the quarter ended March 31, 2026 on Monday, May 4, 2026, after market close. The Company will host a conference call to discuss the results with additional comments and details. Company participants will be Dan Chard, Chairman and Chief Executive Officer, Nick Johnson, President, and Jim Maloney, Chief Financial Officer. The conference call is scheduled to begin at 4:30 p.m. ET on May 4, 2026. The call will be broadcast live over the Internet, hosted on the Investor Relations section of Medifast's website at www.MedifastInc.com or
Medifast (NYSE:MED), the health and wellness company known for its science-backed, coach-guided lifestyle system, today reported results for the fourth quarter and full year ended December 31, 2025. Fourth Quarter 2025 Revenue of $75.1 million, with revenue per active earning coach of $4,664 Independent active earning coaches of 16,100 Net loss of $18.1 million, or $1.65 per diluted share ("EPS"), which includes the tax provision charge to establish a non-cash valuation allowance on the Company's deferred tax balance of $12.1 million (or $1.10 per diluted share) Cash, cash equivalents, and investment Securities of $167.3 million and no debt Full Year 2025 Revenue of $385
Medifast (NYSE:MED), the health and wellness company known for its science-backed, coach-guided lifestyle system, will announce financial results for the quarter and full year ended December 31, 2025 on Tuesday, February 17, 2026, after market close. The Company will host a conference call to discuss the results with additional comments and details. Company participants will be Dan Chard, Chairman and Chief Executive Officer, Nick Johnson, President, and Jim Maloney, Chief Financial Officer. The conference call is scheduled to begin at 4:30 p.m. ET on February 17, 2026. The call will be broadcast live over the Internet, hosted on the Investor Relations section of Medifast's website at www
Medifast (NYSE:MED), the health and wellness company known for its science-backed, coach-guided lifestyle system, today reported results for the third quarter ended September 30, 2025. Third Quarter 2025 Revenue: $89.4 million, with revenue per active earning coach of $4,585 Active Coaches: Independent active earning OPTAVIA® coaches of 19,500 Net Loss: $2.3 million or $0.21 loss per diluted share Strong Balance Sheet: $173.5 million in cash, cash equivalents, and investment securities with no debt "We're transforming Medifast from a weight-loss company into a leader in promoting metabolic health," said Dan Chard, Chairman and Chief Executive Officer of Medifast. "Our clini
Medifast (NYSE:MED), the 40+ year old health and wellness company known for its science-backed, coach-guided lifestyle system, will announce financial results for the quarter ended September 30, 2025 on Monday, November 3, 2025, after market close. The Company will host a conference call to discuss the results with additional comments and details. Company participants will be Dan Chard, Chairman and Chief Executive Officer, and Jim Maloney, Chief Financial Officer. The conference call is scheduled to begin at 4:30 p.m. ET on November 3, 2025. The call will be broadcast live over the Internet, hosted on the Investor Relations section of Medifast's website at www.MedifastInc.com or directly
Medifast (NYSE:MED), the health and wellness company known for its habit-based and coach-guided lifestyle solution, OPTAVIA®, today reported results for the second quarter ended June 30, 2025. Second Quarter 2025 Revenue: $105.6 million, with revenue per active earning coach of $4,630 Active Coaches: Independent active earning OPTAVIA coaches of 22,800 Net Income: $2.5 million or $0.22 per diluted share, which includes a gain on investment in LifeMD (NASDAQ:LFMD) common stock of $2.0 million (net of tax) Strong Balance Sheet: $162.7 million in cash, cash equivalents, and investment securities with no debt "We are working diligently to transform our business as we look to he
Medifast (NYSE:MED), the health and wellness company known for its habit-based and coach-guided lifestyle solution, OPTAVIA®, will announce financial results for the quarter ended June 30, 2025 on Monday, August 4, 2025, after market close. The Company will host a conference call to discuss the results with additional comments and details. Company participants will be Dan Chard, Chairman and Chief Executive Officer, and Jim Maloney, Chief Financial Officer. The conference call is scheduled to begin at 4:30 p.m. ET on August 4, 2025. The call will be broadcast live over the Internet, hosted on the Investor Relations section of Medifast's website at www.MedifastInc.com or directly at https:
Medifast (NYSE:MED), the health and wellness company known for its habit-based and coach-guided lifestyle solution, OPTAVIA®, today reported results for the first quarter ended March 31, 2025. First Quarter 2025 Revenue of $115.7 million, with revenue per active earning coach of $4,556 Independent active earning OPTAVIA coaches of 25,400 Net loss of $0.8 million, which includes an unrealized gain on investment in LifeMD (NASDAQ:LFMD) common stock of $0.4 million (net of tax) Loss per share of $0.07 Cash, Cash Equivalents, and Investment Securities of $164.6 million with no debt "In today's health and wellness landscape, more people than ever are seeking guidance not just for we
Medifast (NYSE:MED), the health and wellness company known for its habit-based and coach-guided lifestyle solution, OPTAVIA®, will announce financial results for the quarter ended March 31, 2025 on Monday, April 28, 2025, after market close. The Company will host a conference call to discuss the results with additional comments and details. Company participants will be Dan Chard, Chairman and Chief Executive Officer, and Jim Maloney, Chief Financial Officer. The conference call is scheduled to begin at 4:30 p.m. ET on April 28, 2025. The call will be broadcast live over the Internet, hosted on the Investor Relations section of Medifast's website at www.MedifastInc.com or directly at https: